BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced the appointment of Narinder Singh as Executive Vice President, Technical Operations. Mr. Singh is a proven biopharmaceutical executive with over two decades of deep technical, operational, and strategic leadership experience in end-to-end biopharmaceutical clinical development and commercialization, launch, and life cycle management for a variety of biopharmaceuticals such as biologics, biosimilars, complex generics, peptide vaccines and T-cell therapies.
“I am delighted to welcome Narinder, whose deep technical development, manufacturing and supply chain operations experience will be invaluable as we continue to support the launch of PALFORZIA® in the U.S and the potential launch of PALFORZIA in Europe next year,” said Jayson Dallas, M.D., President and CEO of Aimmune Therapeutics. “His appointment further strengthens our Leadership Team as we continue to build our global commercial footprint. Moreover, his experience across a variety of biopharmaceuticals is highly relevant as we advance our pipeline, including our monoclonal antibody AIMab7195.”
Prior to joining Aimmune, Mr. Singh was Senior Vice President, Pharmaceutical Sciences and Manufacturing at Genocea Biosciences where he was instrumental in technical development and building manufacturing supply chain operations for a personalized neoantigen-based vaccine and T-cell therapy for solid cancers. Prior to Genocea, Narinder served at Momenta Pharmaceuticals and at Amgen Inc. for 18 years in a variety of leadership roles in drug product and combination device development, commercialization, and manufacturing operations. Narinder holds a B.Tech/M.Tech in Biochemical Engineering and Biotechnology from the Indian Institute of Technology in Delhi, India; an M.S. in Chemical Engineering from the University of Houston, and; an M.B.A. from the UCLA Anderson School of Management.
“I am thrilled to join the leadership team at Aimmune and to be part of advancing the company’s mission. I look forward to the opportunity to be part of the development of first-in-class medicines that have the potential to change the lives of children and families living with life-threatening food allergies,” said Mr. Singh.
Aimmune Therapeutics, Inc. is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies. For more information, please visit www.aimmune.com.
Statements contained in this press regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Aimmune’s expectations regarding the launch of PALFORZIA in the United States; the potential approval of and launch timing for AR101 in Europe; and potential applications of the CODIT approach to treating life-threatening food allergies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the risk that the COVID-19 worldwide pandemic may continue to negatively impact the business, research and clinical operations of Aimmune or its partners; Aimmune’s or any of its collaborative partners’ ability to initiate and/or complete clinical trials; the unpredictability of the regulatory process; the possibility that Aimmune’s or any of its collaborative partners’ clinical trials will not be successful; Aimmune’s dependence on the success of PALFORZIA; Aimmune’s reliance on third parties for the manufacture of Aimmune’s products and product candidates; possible regulatory developments in the United States and foreign countries; and Aimmune’s ability to attract and retain senior management personnel. These and other risks and uncertainties are described more fully in Aimmune's most recent filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
This press release concerns PALFORZIA, which has been approved for marketing by the FDA in the United States and has not been approved for marketing by the EMA or Swissmedic. PALFORZIA in Europe is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.
PALFORZIA®, AIMMUNE®, AIMMUNE THERAPEUTICS® and CODIT™ are trademarks of Aimmune Therapeutics, Inc.